Electronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians

被引:13
|
作者
Chan, Alexandre [1 ,2 ]
Yap, Kevin Yi-Lwern [3 ]
Koh, Dorothy [1 ]
Low, Xiu Hui [1 ]
Cheung, Yin Ting [1 ]
机构
[1] Natl Univ Singapore, Dept Pharm, Fac Sci, Singapore 117543, Singapore
[2] Natl Canc Ctr Singapore, Dept Pharm, Singapore, Singapore
[3] Univ Warwick, Inst Digital Healthcare, WMG, Coventry CV4 7AL, W Midlands, England
关键词
oral anticancer drugs; antidepressants; drug-drug interactions; prevalence; co-prescription; TAMOXIFEN; CHEMOTHERAPY; INHIBITORS;
D O I
10.1002/pds.2167
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Electronic drug interaction databases are often utilized in clinical practice to detect for possible drug-drug interactions between drug pairs. It is uncertain, however, whether most of these detections interactions are clinically important in practice. To demonstrate these issues, this study utilized a comprehensive drug-drug interaction( DDI) electronic database to elucidate the prevalence of DDIs at a cancer centre between antidepressants and oral anticancer drugs( ACDs). Methods Drug utilization reports were retrieved to determine the patients who were prescribed with antidepressants oral ACDs between 2006 and 2009 at a cancer center. Medication records of these patients were retrospectively examined using OncoRx, an internet-based oncology-specific database that allows the identification of DDIs. Results Out of 910 users of antidepressants, about one-third( 281 patients, 30.9%) used an oral ACD and an antidepressant concomitantly. From these patients, about one-fifth( 21.0%) had potential DDIs. These patients were users of 17 potentially interacting drug pairs. Ten out of the 17 drug pairs could potentially cause pharmacokinetic interactions, and the rest were pharmacodynamic interactions, with only three out of the 17 drug pairs were clinically documented to cause interacting events. Conclusion The lack of screening conditions may have led to an over detection of DDI combinations by electronic DDI databases. Many of the detected interactions may not deem high significance in clinical practice. This study exposed a major weakness of current electronic DDI databases for detecting oral ACDs and antidepressants DDIs. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:939 / 947
页数:9
相关论文
共 37 条
  • [31] Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males
    Sasaki, Takashi
    Seino, Yutaka
    Fukatsu, Atsushi
    Ubukata, Michito
    Sakai, Soichi
    Samukawa, Yoshishige
    ADVANCES IN THERAPY, 2015, 32 (05) : 404 - 417
  • [32] DRUG-DRUG INTERACTIONS BETWEEN CENOBAMATE AND OTHER ANTIEPILEPTIC DRUGS: RESULTS FROM PHASE I STUDIES WITH CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, AND DIVALPROEX SODIUM.
    Vernillet, L.
    Kamin, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S91 - S91
  • [33] Analysis of hemorrhagic drug-drug interactions between P-gp inhibitors and direct oral anticoagulants from the FDA Adverse Event Reporting System
    Li, Mengyao
    Xiao, Jian
    Yu, Ting
    Huang, Ling
    Cai, Ruwen
    Yu, Huimin
    Li, Jingyang
    Cheng, Shuqiao
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [34] Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer
    Gulikers, Judith L.
    Otten, Leila-Sophie
    Hendriks, Lizza E. L.
    Winckers, Kristien
    Henskens, Yvonne
    Leentjens, Jenneke
    van den Heuvel, Michel M.
    ter Heine, Rob
    Croes, Sander
    Piet, Berber
    van Geel, Robin M. J. M.
    BRITISH JOURNAL OF CANCER, 2024, 131 (02) : 299 - 304
  • [35] The Prevalence of Selected Potential Drug-Drug Interactions of Analgesic Drugs and Possible Methods of Preventing Them: Lessons Learned From the Analysis of the Real-World National Database of 38 Million Citizens of Poland
    Kardas, Przemyslaw
    Urbanski, Filip
    Lichwierowicz, Aneta
    Chudzynska, Ewa
    Czech, Marcin
    Makowska, Katarzyna
    Kardas, Grzegorz
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [36] Evaluation of drug-drug interactions (DDI) between tucatinib and capecitabine (C) in patients with advanced HER plus metastatic breast cancer from a phase 1b study
    Vo, A.
    Leviten, D.
    Insko, M.
    Sierra, T.
    Dozier, A.
    Walker, L.
    Peterson, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Potential Interactions Between HIV Drugs, Ritonavir and Efavirenz and Anticancer Drug, Nilotinib-A Study in Primary Cultures of Human Hepatocytes That Is Applicable to HIV Patients With Cancer
    Pillai, Venkateswaran C.
    Parise, Robert A.
    Christner, Susan M.
    Rudek, Michelle A.
    Beumer, Jan H.
    Venkataramanan, Raman
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (11): : 1272 - 1279